PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2009 | 58 | 1-2 | 113-125
Article title

System wspomagania wytwarzania i analiz szczepionek genetycznych

Content
Title variants
EN
Genetic vaccine decision support system
Languages of publication
PL EN
Abstracts
EN
Genetic vaccines and especially recombinant viral vectors and virus-like particles are considered the most promising vehicles for delivery of antigens in prophylactic and therapeutic vaccines against infectious diseases and cancer. Several potential vaccine design systems exist but their cost-effective development cruelly lacks a standardized evaluation system. Solving the problem Genetic Vaccine Decision Support system (GeVaDSs, http://www.compuvac.org) has been implemented as a part of CompuVac project realized within 6th Framework Program of European Commission. Using GeVaDSs we have successfully developed and standardized methods for evaluation of the efficacy and safety of individual vaccine vectors, in a manner that allows comparison between different vaccine designs, tested in different laboratories, at different time points. With these methods, the efficacy of a unique set of vaccines has been analyzed and compared with an intelligent database. GeVaDSs has allowed to make significant comparisons between different types of vaccines and to initiate novel vaccine design and vaccination regimens. Besides monitoring of T- and B-cell immune responses, GeVaDSs is also aimed at monitoring vaccine "efficacy" and "safety" profiles by analyzing relevant molecular signatures obtained from transcriptomes studies. The "efficacy" and the "safety profile" have been validated, based on analyzing molecular signatures from whole liver and spleen after injection of vaccine vectors. The results of these experiments will drive the development of HCV vaccines. The first HCV vectors generated in single immunization regimen were tested, and interesting results obtained suggest the great potential for the association of our two classes of vectors, viral and VLP derived.
Keywords
Journal
Year
Volume
58
Issue
1-2
Pages
113-125
Physical description
Dates
published
2009
References
  • Belakova J., Horynova M., Krupka M., Weigl E., Raska M., 2007. DNA vaccines: are they still just a powerful tool for the future? Arch. Immunol. Ther. Exp. 55, 387-398.
  • Błażewicz J., Łukasiak P., Wojciechowski P., Kędziora P., Borowski M., Dziurdza B., 2006. GeVaDSs - implementation and functionality. Report No 30, Poznan University of Technology, Poznań
  • Błażewicz J., Łukasiak P., Wojciechowski P., Kędziora P., Borowski M., Błażewicz M., 2008. GeVaDSs - user manual 5.0. Report No 38, Poznan University of Technology, Poznań.
  • Costa F., Franchin G., Pereira-choccola V. L., Ribeiaro M., Schekman S., Rodrigues M. M., 1998. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma crusi infection in mice. Vaccine 16, 768-774.
  • Danko I., Wolff J. A., 1994. Direct gene transfer into muscle. Vaccine 12, S1499-S1502.
  • Drew D. R., Lightowlers M., Strugnell R. A., 2000. Humoral immune responses to DNA vaccinesexpressingsecreted, membrane bound and non-secreted forms of the Taenia ovis 45W antigen. Vaccine 18, 2522-2532.
  • Ertl H. C. J., Xiang Z., 1996. Novel vaccine approaches. J. Immunol. 156, 3579-3582.
  • Hoffman S. L., Doolan D. L., Sedegah M., Aguiar J. C., Wang R., Malik A., Gramzinski R. A., Weiss W. R., Hobart P., Norman J. A., Margalith M., Hedstrom R. C., 1997. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine 15, 842-845.
  • Jakóbisiak M., 2002. Immunologia. Wydanie Naukowe PWN, Warszawa.
  • Kofta W., Wędrychowicz H., 2001. c-DNA vaccination against parasitic infections: advantages and disadvantages. Vet. Parasitol. 94, 243-247.
  • Łukasiak P., Błażewicz J., Klatzmann., 2007. GeVaDSs - system for new improved vaccines based on genomic and proteomic information. ICOLE'08 - German-Polish Workshop on Computational Biology, Perspectives of Bioinformatics, Operations Research and Machine Learning, June, 2008, Lessach, Austria.
  • Peachman K. K., Rao M., Alving C. R., 2003. Immunization with DNA through the skin. Methods 31, 232-242.
  • Piekarowicz A., 2004. Podstawy wirusologii molekularnej. Wydawnictwo naukowe PWN, Warszawa.
  • Reyes-Sandoval A, Ertl H. C., 2001. DNA vaccines Curr. Mol. Med. 1, 217-43.
  • Manoj S., Babiuk L. A., van Drunen Littel-Van Den Hurk S., 2004. Approaches to enhance the efficacy of DNA vaccines. Crit. Rev. Clin. Lab. Sci. 41, 1-3.
  • Rogan D., Babiuk L. A., 2005. Novel vaccines from biotechnology. Rev. Sci. Tech. Off. Int. Epiz. 24, 159-174.
  • Schneider R. J., Mohr I. 2003. Translation initiation and viral tricks. Trends. Bioch. Sci. 28, 130.
  • Siegrist C. A., 1997 Potential advantages and risks of nucleic acid vaccines for infant immunization. Vaccine 15, 798-800.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-ksv58p113kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.